3 Shares Analysts Hate: GlaxoSmithKline plc, Standard Chartered PLC And Anglo American plc

Here’s why GlaxoSmithKline plc (LON:GSK), Standard Chartered PLC (LON:STAN) and Anglo American plc (LON:AAL) are out of favour with City experts.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now, GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US), Standard Chartered (LSE: STAN) and Anglo American (LSE: AAL) are not winning friends among City analysts. Here’s why.


It wasn’t so long ago that GlaxoSmithKline was the City experts’ favoured pharmaceuticals firm, while AstraZeneca was thoroughly unloved. How times change! Over the past year we’ve seen a series of downgrades to Glaxo’s earnings forecasts (from 114p a share 12 months ago to 80p a share today), along with a swing to negative recommendations; more analysts now rate Glaxo a Sell than a Buy.

Underwhelming Q1 results last month, and the board’s decision to hold the dividend at 80p a share for the next three years, saw bearish analysts reiterate their negative stance, and a number of previously bullish brokers move from Buy to Neutral.

Even Glaxo’s house broker Citigroup sounded downbeat, mentioning — among other things — Glaxo’s “inability to compete on a level playing field in China” (since last year’s bribery scandal) and “constrain[ed] relative commercial effectiveness in the US compared with peers” (due to an onerous US corporate integrity agreement that still has 2.5 years to run).

Nevertheless, private investors taking a longer-term view than CIty number crunchers may feel Glaxo’s shares are attractive at current depressed sub-£14 levels with a juicy 5.8% dividend yield — albeit with the yield being static for three years.

Standard Chartered

Analysts’ earnings downgrades for Standard Chartered over the past year have been even more dramatic than those for Glaxo, moving from 136p a share 12 months ago to 87p today. Nearly twice as many analysts now rate the troubled Asia-focused bank — which has had a boardroom clear out — as a Sell than as a Buy.

Analysts at Jefferies International are uber-bears on StanChart, and have recently further slashed their target price from 722p to 656p (the shares are currently trading at over £10). Many analysts who are negative on the stock are concerned about the bank’s capital ratios — and the impact of potential asset sales/dividend cut/rights issue — but Jefferies’ analysts are particularly downbeat. They believe that whatever route StanChart takes to improve its capital ratios “the earnings power of the bank is likely to be far below what the consensus expects”.

The consensus currently has StanChart on a P/E of 12, with a dividend yield of 4.6%. On the face of it, the valuation is attractive, but, while I don’t view the bank as bleakly as Jefferies, I think it could be prudent to wait and see exactly what the new chief executive’s plans are.

Anglo American

Mining has been far from the City experts’ best-loved sector for some time. But Anglo American — which currently has twice as many Sell ratings as Buy recommendations — is markedly less popular than its big FTSE 100 peers BHP Billiton, Rio Tinto and Glencore. And earnings downgrades for Anglo American over the past year (from 129p a share 12 months ago to 68p a share today), make the downgrades to Glaxo and StanChart appear downright mild!

Of course, the whole mining industry has been hit by falling commodity prices. Anglo American, though, has seen additional issues; including, a hangover from ill-timed acquisitions, slow progress on asset disposals and labour unrest.

Bearish equity analysts are concerned about the pace of restructuring and cost cutting, and cash flow and dividend sustainability (the yield is currently 5.6%). Global credit ratings agency Fitch has also chipped in, commenting: “Elevated leverage, which was driven by the intensive capital spending of previous years remains a primary risk, in our view, and is reflected in the negative outlook”.

Anglo American’s P/E of 14.5 is lower than its Footsie rivals, but I believe Rio Tinto has a better risk-reward profile.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young black colleagues high-fiving each other at work
Investing Articles

2 FTSE 100 value stocks I’d buy for my Stocks and Shares ISA in March!

Now could be a great time for fans of FTSE 100 value stocks to go investing. Here are a couple…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Looking for value stocks? Here’s 1 I’d buy and 1 I’d avoid!

This Fool delves deeper into two value stocks she’s had her eye on and explains why she’s bullish on one,…

Read more »

Young black woman using a mobile phone in a transport facility
Investing Articles

With the Airtel Africa share price in pennies, is it a bargain?

With the Airtel Africa share price having slumped by a quarter in just one month, this shareholder considers some of…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Are these 2 defensive FTSE 100 stocks shrewd buys after recent updates?

This Fool takes a closer look at these FTSE 100 stocks. She admires their defensive traits -- but does that…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

The FTSE 100 closes up after full-year results from leading UK firms – are they buys?

Earnings season brings about a lot of ups and downs for the FTSE 100. Yesterday had some particularly good releases,…

Read more »

artificial intelligence investing algorithms
Investing Articles

Should I buy NVIDIA stock as a British investor?

NVIDIA stock is up two-thirds this year alone. Our writer considers some pros and cons, specifically given that he is…

Read more »

Investing Articles

With £2,000 in excess savings, I’d buy 41 shares in this Warren Buffett dividend stock

Stephen Wright thinks one of the best dividend shares to buy right now might be a Warren Buffett stock that’s…

Read more »

Investing Articles

How many Aviva shares do I need to collect a £100 monthly income?

Aviva shares are well suited for passive income purposes. Our writer works out how many would be needed for a…

Read more »